Curiteva, a medical expertise firm, has efficiently handled greater than 5,000 ranges utilizing the Encourage Cervical implant, simply two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D printed trabecular PEEK implant.
“I’ve seen exceptional radiographic proof with the Encourage platform, together with seen bone development inside the graft window and thru the implant inside simply 3 to six months. This offers clinicians with an unparalleled capacity to evaluate therapeutic and progress reliably,” mentioned Chambliss Harrod, MD from The Backbone Middle of Louisiana.
“With this implant, I usually require little to no bracing and have considerably larger confidence in each fusion charges and affected person satisfaction throughout multilevel ACDF procedures,” mentioned John Johnson, MD from SportsMed Orthopedic Surgical procedure and Backbone Middle in Alabama.
“After utilizing Allograft for 30+ years, I’ve lastly discovered a viable substitute for bone. These Curiteva implants have the potential to revolutionize not solely backbone care but additionally a variety of different functions the place beforehand bone may need been used. This expertise has set a brand new customary in affected person care by means of its progressive design and distinctive biomechanical and potential organic properties,” mentioned Mark N. Hadley, MD from the College of Alabama Division of Neurosurgery in Birmingham, Alabama.
Engineered with Curiteva’s proprietary and internally developed FFF 3D printers, Encourage implants characteristic a completely interconnected and built-in porous construction traversing the complete implant. Mixed with its HAFUSE sub-micron nano-texturing, the Encourage implant promotes through-growth, making a superior organic surroundings for bone integration.
Curiteva plans a full industrial launch after a profitable alpha launch of the Encourage TLIF Anterior and Encourage TLIF Indirect implants later this month. Moreover, the corporate is ready to roll out alpha launches for its ALIF portfolio, encompassing Monolithic, Thoracolumbar Plate, and Standalone implants later this yr.
“These achievements mirror the synergy of progressive expertise, world-class manufacturing, vibrant partnerships, and scientific belief,” mentioned Chad Falciani, Founder and Chairman of the Board at Curiteva.
